Chase Reece, BSHP '24

My work today continued to focus on reviewing background CDTM literature. Overall, the literature reveals that the lack of existing policies around CDTM and comprehensive medication management continues to be one of its most significant barriers to adoption. While at least limited CDTM practice is allowed in 49 of the 50 states (all but Delaware), only 11 states allow pharmacists to register with the Drug Enforcement Administration. In order to prescribe controlled substances involved in pain management, substance use treatment, and mental health treatment, a DEA license is required. Research has shown that states that allow DEA-registered pharmacists improve cost savings, improve medication adherence, and increase access to care. Rural populations commonly have higher rates of psychological distress, opioid use, and substance use disorders, while also having less access to treatment for these conditions. Expanding the access to DEA-registered pharmacists has been proven to reduce the morphine equivalent daily dose for pain management patients and improve compliance with opioid risk mitigation strategies, while also capturing many patients who were previously lost to follow-up. This area of CDTM is not widely studied, so further research into its implications and analysis from a policy standpoint are needed, but it appears to be a potentially useful method for improving access to care for prominent health conditions in rural areas.